GlobeNewsWire
04 Aug 2026, 23:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics allegedly resubmitted its Deramiocel Biologics License Application (BLA) without prior FDA agreement on changes to its statistical analysis plan. — Lack of FDA alignment on clinical data analysis significantly increases the risk of a regulatory rejection for the company's lead candidate.
-0.80The lawsuit claims there is a substantial risk that the FDA may conclude Deramiocel does not provide substantial evidence of effectiveness for Duchenne muscular dystrophy. — Directly challenges the core value proposition and future revenue potential of the company's primary cell therapy product.
-0.70A class action lawsuit has been filed against Capricor Therapeutics for making materially false or misleading statements regarding its business operations and prospects. — Legal challenges create overhead costs and signal potential governance failures, though they are secondary to the underlying clinical/regulatory risks.
-0.40Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a class action lawsuit alleging misleading statements regarding FDA processes and clinical data for Deramiocel.
The company is under investigation by a law firm for potential securities claims.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
4h ago
